Once-Weekly Mosnodenvir Shows Promise as Dengue Prophylaxis in Human Infection Model

New research published in The New England Journal of Medicine indicates that once-weekly mosnodenvir, a small-molecule antiviral, demonstrated protective effects in a human challenge model for dengue. This finding suggests its potential as a prophylactic treatment for dengue, a disease for which no antiviral therapy is currently approved.